MAGEA4 and sarcoma: Vaccines targeting New York esophageal squamous cell carcinoma 1 (NYESO‐1) [28, 29] and TCR‐T therapies targeting NYESO‐1 [30] or melanoma‐associated antigen A4 (MAGE‐A4) [31] are reported under clinical trials, making CTAs an attractive therapeutic target for sarcomas.